



RUCHI NAHAR

Research Analyst

BLISS GVS PHARMA LTD

DATE 04 JULY 2024

About Company

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Bliss GVS is a Pharmaceutical Company with a track record of developing, manufacturing and marketing pharmaceutical formulations at affordable prices for the global market. They are a public limited company listed on India's National Stock Exchange and Bombay Stock Exchange with more than three decades of industry expertise.

They are among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, They have acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by their ever-expanding product offering across more than sixty countries.


With significant expansion in R & D, Manufacturing & Marketing capabilities, They are poised for an accelerated rate of growth.

OUR RECOMMENDATION:


MOMENTUM SWING: BUY BLISSGVS BETWEEN 110.50-111.50 TARGETS 117-126 STOP LOSS BELOW 103

MARKET CAP	P/E	DIVIDEND YIELD	ROCE	ROE	FACE VALUE	3 YEARS SALES GROWTH	3 YEARS PROFIT GROWTH
RS. 1,163CR.	12	0.47%	15%	10%	1.00	10%	11%


QOQ SALES (IN CR.)



QOQ NET PROFIT (IN CR.)



SHAREHOLDING PATTERN MARCH 24



Analyst View

BLISS GVS clearly gave breakout on daily chart. The stock bounced back from the support of Super Trend and sustained above super trend indicator. The rising volume in 30 min chart and breakout indicates that stock is expected to give a bullish trend. Company shows a YOY sales growth from past 3 years. In the last 3 years Net Profit has jumped significantly from Rs.23 cr. to Rs.82 cr. On the basis of above

information we gave Buy signal in the stock, also the breakout shows a momentum in short term. Hence buy recommendation was given in the stock.

DISCLAIMER

I, **Ruchi Nahar**, SEBI Registered Research Analyst (**INH000014544**) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. **I have qualified CA, CS and MBA**, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverages my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons

that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Ranahaz